Trial Profile
A Phase 1 Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Upfront Treatment of Advanced Colorectal and Gastric Cancer With a Dose Expansion Cohort in Advanced Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2016
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- 31 Mar 2016 New trial record